Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for ImmunityBio in a research report issued on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.06) for the quarter, up from their previous forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ImmunityBio’s Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.40) EPS, FY2029 earnings at $0.94 EPS and FY2030 earnings at $1.39 EPS.

A number of other analysts have also commented on IBRX. BTIG Research reaffirmed a “buy” rating and issued a $12.00 price target on shares of ImmunityBio in a research note on Thursday, May 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ImmunityBio has an average rating of “Moderate Buy” and a consensus price target of $14.20.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $7.25 on Thursday. ImmunityBio has a fifty-two week low of $1.95 and a fifty-two week high of $12.43. The firm has a market cap of $7.59 billion, a P/E ratio of -7.47 and a beta of 0.03. The business’s 50 day moving average price is $7.66 and its 200-day moving average price is $7.64.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to the consensus estimate of $49.70 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in ImmunityBio by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after acquiring an additional 5,122,052 shares in the last quarter. State Street Corp increased its holdings in shares of ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after acquiring an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of ImmunityBio by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock valued at $15,684,000 after acquiring an additional 1,030,113 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of ImmunityBio by 439.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after purchasing an additional 5,012,001 shares during the last quarter. Finally, Woodline Partners LP raised its position in shares of ImmunityBio by 53.7% in the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock worth $13,032,000 after purchasing an additional 1,851,854 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Insiders Place Their Bets

In other ImmunityBio news, Director Christobel Selecky sold 159,478 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $9.02, for a total transaction of $1,438,491.56. Following the completion of the transaction, the director owned 35,064 shares of the company’s stock, valued at approximately $316,277.28. This trade represents a 81.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the transaction, the director owned 125,386 shares of the company’s stock, valued at $1,191,167. The trade was a 51.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 435,443 shares of company stock worth $3,918,819. 66.10% of the stock is currently owned by company insiders.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Record Anktiva-driven revenue growth: ImmunityBio reported second-quarter net product revenue of $50.7 million, up 92% year over year and 15% sequentially. First-half revenue reached $94.8 million, a 121% increase, indicating continued commercial adoption of Anktiva. ImmunityBio Reports Record Q2 2026 Net Product Revenue
• Positive Sentiment: Revenue exceeded expectations: Quarterly revenue of $51.24 million surpassed the $49.70 million analyst consensus, with coverage highlighting strong Anktiva uptake and additional regulatory milestones ahead. IBRX Q2 Earnings and Sales Beat Estimates
• Neutral Sentiment: Analyst outlook remains bullish but estimates are mixed: HC Wainwright reiterated its “Buy” rating and $15 price target. It raised Q3 2026 and Q4 2026 EPS forecasts slightly and increased its FY2027 estimate to $0.07, but lowered FY2026 EPS to $(0.40) from $(0.28), FY2029 to $0.94 from $0.95, and FY2030 to $1.39 from $1.41.
• Negative Sentiment: Reported earnings miss: ImmunityBio posted a quarterly loss of $(0.22) per share, well below the consensus loss estimate of $(0.08), despite beating on revenue. The earnings shortfall triggered a gap-down reaction and highlights ongoing profitability risk as the company expands commercialization. ImmunityBio Shares Gap Down After Earnings Miss

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.